ARQT250516C30000
- 0.00
- 0.000.00%
Arcutis Biotherapeutics Newsroom
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $19 to $21
Analysts Are Bullish on These Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Praxis Precision Medicines (PRAX)
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
Arcutis Biotherapeutics: Buy Rating Affirmed Amid Positive Long-Term Outlook and Strategic Growth Potential
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
Arcutis Biotherapeutics Analyst Ratings
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $21
H.C. Wainwright Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $19
Arcutis Biotherapeutics Analyst Ratings
Strategic Advantage and Market Confidence: Arcutis Biotherapeutics' Extended Exclusivity and Buy Rating Amidst Competitive Risks
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $20 Price Target
Arcutis Biotherapeutics (ARQT) Receives a Buy From Mizuho Securities
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)
Jefferies Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $19
Arcutis Biotherapeutics Analyst Ratings
Jefferies Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $19